CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Maraviroc+Favipiravir+CTWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (5)

Name (Synonyms) Correlation
drug1433 Maraviroc + Currently used therapy Wiki 1.00
drug32 2: continuation of RAS blocker therapy Wiki 1.00
drug21 1: discontinuation of RAS blocker therapy Wiki 1.00
drug689 Curently used therapy for COVID-19 non-critical patients Wiki 1.00
drug928 Favipiravir + Currently used therapy Wiki 1.00

Correlated MeSH Terms (2)

Name (Synonyms) Correlation
D002318 Cardiovascular Diseases NIH 0.21
D007239 Infection NIH 0.06

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0001626 Abnormality of the cardiovascular system HPO 0.21

There is one clinical trial.

Clinical Trials

1 A Controlled, Phase 2, Randomized Study to Evaluate Safety and Efficacy of Oral Maraviroc and/or Favipiravir vs Currently Used Therapy in Severe Adults With COVID-19

Phase 2, randomized, open-label study to compare the safety and efficacy of maraviroc, favipiravir, and both drugs combined versus currently used therapy in hospitalized patients with pulmonary SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) infection (COVID-19)

NCT04475991 COVID-19 Drug: Maraviroc + Currently used therapy Procedure: Curently used therapy for COVID-19 non-critical patients Drug: Favipiravir + Currently used therapy Drug: Maraviroc+Favipiravir+CT

Primary Outcomes

Description: Percentage of patients free of mechanical ventilation or death

Measure: Patients free of mechanical ventilation or death

Time: 28 days post start

Secondary Outcomes

Description: Percentage of patients free of mechanical ventilation or death

Measure: Patients free of mechanical ventilation or death

Time: 5 days post start

Description: Time of improvement in at least 2 items of the 7-item World Health Organization (WHO) ordinal scale for COVID-19 in days.

Measure: Time of clinical improvement

Time: 15 days post start

Description: Rate of change (Delta) in lymphocytes, monocytes and neutrophils with phosphorilated CCR5 as per measured by parameters of flow cytometry.

Measure: Rate of change in phosphorilated CCR5

Time: Day 10-1

Description: Rate of change (Delta) in peripheral blood levels of proinflammatory cytokines and chemokynes [IL-6, IL-1b, TNF, IFNa, IFNg, VEGF, GM-CSF (granulocyte-macrophage colony stimulating factor), CCL2, CCL3, CCL4, CCL5, CXCL10 and CCL7], as per measured by parameters of flow cytometry

Measure: Rate of change in peripheral blood levels of proinflammatory cytokines and chemokynes

Time: Day 10-1

Description: Statistically significant change in the expression of activation [phosphorylated CCR5,CD38, CD126, CD127, CD25, CD86, CD83, CD40 (cluters of differentiation 38, 126, 127, 25, 86 and 40), HLA-DR (Human Leukocyte Antigen-DR isotype), Granzyme B, Perforin, CD107A, CD123, gp130, CD95], trafficking [CCR5, CCR2, CCR6, CCR7, CXCR1, CXCR3 , CXCR5, (CXC chemokine receptors 1, 3 and 5), CX3CR1 (CX3C chemokine receptor] and exhaustion (PD1, programmed death-1 receptor) markers in peripheral blood lymphocytes, neutrophils and monocytes, as per measured by parameters of flow cytometry.

Measure: Change in the trafficking and activation pattern of peripheral leukocytes

Time: Day 10-1

No related HPO nodes (Using clinical trials)